Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

89bio Q4 EPS $(0.48) Beats $(0.69) Estimate

89bio (NASDAQ:ETNB) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.69) by 30.43 percent. This is a 63.08 percent increase over losses of $(1.30) per share from the same
byBenzinga Newsdesk
March 10, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

89bio (NASDAQ:ETNB) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.69) by 30.43 percent. This is a 63.08 percent increase over losses of $(1.30) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

SELLAS Life Sciences To Present Final Data From Phase 1/2 Study Of Galinpepimut-S In Combination With Keytruda In Patients With WT1+ Platinum-Resistant Advanced Ovarian Cancer At The International Gynecologic Cancer Society 2023 Annual Global Meeting

By Benzinga Newsdesk
October 17, 8:45 AM
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today

SLS